Neurotrophin-related signalling
Astrocyte and animal studies have examined BDNF-related responses following Semax exposure.

Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
Lyophilized Peptide — Single vial
Semax 10 mg supplied exclusively as a laboratory research material. Available batch documentation is published only under its corresponding batch record.
Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
RESEARCH & TECHNICAL OVERVIEW
Semax is a synthetic heptapeptide derived from the ACTH(4–7) sequence and extended with Pro-Gly-Pro. The intact heptapeptide is synthetic rather than a naturally occurring hormone.
Published research has examined neurotrophin-related signalling, gene-expression responses and experimental cerebral-ischaemia models. The evidence includes cellular and animal work, with a smaller body of human research.
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
HANDLING INFORMATION
An exact post-reconstitution storage period has not been established for this formulation.
MedChemExpress — Semax technical record ↗SCIENTIFIC CONTEXT
Longer technical information is grouped for easier reading on desktop and mobile.
Semax is structurally related to a fragment of adrenocorticotropic hormone (ACTH), an endogenous peptide hormone. The Pro-Gly-Pro extension creates a distinct synthetic research compound.
The current NOREXA record names Semax but does not publish a counter-ion or supplier-confirmed salt form.
Astrocyte and animal studies have examined BDNF-related responses following Semax exposure.
Rat focal-ischaemia studies reported changes in immune- and vascular-system gene expression.
Protein-expression studies in rat brain models have examined CREB, JNK, c-Fos and MMP-9 responses.
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
CURRENT BATCH / LOT
No identity, purity, quantity or batch number is shown as independently verified until exact product-and-lot evidence is available.
OPEN CENTRAL BATCH VERIFICATION →HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
Batch documentation and independent reports are shown only when published for the exact corresponding batch.
CHEMICAL IDENTITY REFERENCE ↗SELECTED SOURCES
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
Journal of Neurochemistry · 2006
BMC Genomics · 2014
International Journal of Molecular Sciences · 2021
PRODUCT FAQ
No. It is a synthetic peptide based on an ACTH fragment and extended with Pro-Gly-Pro.
The public record identifies CAS 80714-61-0, formula C37H51N9O10S and the MEHFPGP sequence. No acetate or other counter-ion is assumed.
The selected literature covers neurotrophin-related responses, transcriptomics and experimental neural-stress models.
Only the aqueous laboratory-stock condition for a reference matching the displayed CAS number, formula and sequence. No bacteriostatic-water refrigerator period is inferred.
SECTION 01 — STANDARDS
01 / 03Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Available batch documentation is organized under the corresponding batch number for clear reference.
NOREXA PEPTIDES
RESEARCH ACCESS
Please confirm before entering the website.
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE